HomeCompareBRIBF vs EPRT

BRIBF vs EPRT: Dividend Comparison 2026

BRIBF yields 1062.70% · EPRT yields 3.92%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 BRIBF wins by $32084463.93M in total portfolio value
10 years
BRIBF
BRIBF
● Live price
1062.70%
Share price
$0.19
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$32084464.00M
Annual income
$27,073,008,093,454.87
Full BRIBF calculator →
EPRT
EPRT
● Live price
3.92%
Share price
$30.77
Annual div
$1.21
5Y div CAGR
29%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$63.4K
Annual income
$12,840.73
Full EPRT calculator →

Portfolio growth — BRIBF vs EPRT

📍 BRIBF pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodBRIBFEPRT
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, BRIBF + EPRT cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
BRIBF pays
EPRT pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

BRIBF
Annual income on $10K today (after 15% tax)
$90,329.44/yr
After 10yr DRIP, annual income (after tax)
$23,012,056,879,436.64/yr
EPRT
Annual income on $10K today (after 15% tax)
$332.87/yr
After 10yr DRIP, annual income (after tax)
$10,914.62/yr
At 15% tax rate, BRIBF beats the other by $23,012,056,868,522.02/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of BRIBF + EPRT for your $10,000?

BRIBF: 50%EPRT: 50%
100% EPRT50/50100% BRIBF
Portfolio after 10yr
$16042232.03M
Annual income
$13,536,504,053,147.79/yr
Blended yield
84.38%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on EPRT right now

BRIBF
No analyst data
Altman Z
19.2
Piotroski
2/9
EPRT
Analyst Ratings
1
Strong
17
Buy
3
Hold
1
Sell
Consensus: Buy
Price Target
$35.50
+15.4% upside vs current
Range: $33.00 — $37.00
Altman Z
1.8
Piotroski
5/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

BRIBF buys
0
EPRT buys
0
No recent congressional trades found for BRIBF or EPRT in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricBRIBFEPRT
Forward yield1062.70%3.92%
Annual dividend / share$2.00$1.21
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%29%
Portfolio after 10y$32084464.00M$63.4K
Annual income after 10y$27,073,008,093,454.87$12,840.73
Total dividends collected$31704729.30M$37.9K
Payment frequencyquarterlyquarterly
SectorStockREIT

Year-by-year: BRIBF vs EPRT ($10,000, DRIP)

YearBRIBF PortfolioBRIBF Income/yrEPRT PortfolioEPRT Income/yrGap
1← crossover$116,970$106,269.93$11,205$505.18+$105.8KBRIBF
2$1,286,876$1,161,718.25$12,672$682.46+$1.27MBRIBF
3$13,321,776$11,944,818.28$14,490$930.48+$13.31MBRIBF
4$129,817,926$115,563,625.92$16,786$1,282.69+$129.80MBRIBF
5$1,191,375,681$1,052,470,500.56$19,753$1,791.56+$1191.36MBRIBF
6$10,301,704,979$9,026,933,000.21$23,677$2,541.64+$10301.68MBRIBF
7$83,971,400,363$72,948,576,035.34$29,008$3,672.99+$83971.37MBRIBF
8$645,568,504,677$555,719,106,288.88$36,463$5,425.08+$645568.47MBRIBF
9$4,683,603,649,023$3,992,845,349,018.69$47,238$8,221.57+$4683603.60MBRIBF
10$32,084,463,997,910$27,073,008,093,454.87$63,385$12,840.73+$32084463.93MBRIBF

BRIBF vs EPRT: Complete Analysis 2026

BRIBFStock

Brii Biosciences Limited engages in the development of medicines for the treatment of infectious and central nervous system diseases. The company develops BRII-778 and BRII-732, which are in phase I clinical trials for the treatment of HIV patients; BRII-179 and BRII-835, which are in Phase 2 to evaluate the combination of these two HBV mechanisms for Hepatitis B; BRII-179, a recombinant protein-based HBV immunotherapeutic candidate that is in Phase 1b/2a; BRII-835, which has completed Phase-2 for patients with chronic HBV infection; and Amubarvimab/romlusevimab combination therapy for the treatment of COVID-19. It also develops BRII-296 for the treatment of PPD; BRII-297 for treatment of various depressive disorders; BRII-636, BRII-672, and BRII-693 for the treatment of multi-drug resistant/extensive drug resistant (MDR/XDR) gram-negative infections; and BRII-658 for the treatment of MDR/XDR tuberculosis and non-tuberculosis mycobacteria. The company was incorporated in 2017 and is based in Beijing, China.

Full BRIBF Calculator →

EPRTREIT

Essential Properties Realty Trust, Inc., a real estate company, acquires, owns, and manages single-tenant properties in the United States. The company leases its properties to middle-market companies, such as restaurants, car washes, automotive services, medical and dental services, convenience stores, equipment rental, entertainment, early childhood education, grocery, and health and fitness on a long-term basis. As of December 31, 2021, it had a portfolio of 1, 451 properties. The company qualifies as a real estate investment trust for federal income tax purposes. It generally would not be subject to federal corporate income taxes if it distributes at least 90% of its taxable income to its stockholders. The company was founded in 2016 and is headquartered in Princeton, New Jersey.

Full EPRT Calculator →
📬

Get this BRIBF vs EPRT comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

BRIBF vs SCHDBRIBF vs JEPIBRIBF vs OBRIBF vs KOBRIBF vs MAIN

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.